<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297631</url>
  </required_header>
  <id_info>
    <org_study_id>201911147</org_study_id>
    <nct_id>NCT04297631</nct_id>
  </id_info>
  <brief_title>Intraarticular Antibiotic in TKA</brief_title>
  <official_title>Prospective Study Investigating Antibiotic Elution From Free Intra-articular Vancomycin and Tobramycin After Cementless Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the intra-articular concentration of vancomycin and&#xD;
      tobramycin after administration of vancomycin and tobramycin powder in primary cementless&#xD;
      total knee arthroplasty and determine the serum concentrations of these antibiotics&#xD;
      postoperatively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be identified by medical record review to make sure they meet inclusion and&#xD;
      exclusion criteria. Patients that qualify and sign consent will have tobramycin and&#xD;
      vancomycin antibiotic powder placed into the knee during surgery. Postoperative drain fluid&#xD;
      from the knee will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Antibiotics in Cementless Knees Post op</measure>
    <time_frame>1 hour, 4 hours, and 24 hours</time_frame>
    <description>1. Determine the intra-articular concentration of vancomycin and tobramycin after administration of vancomycin and tobramycin powder in primary cementless total knee arthroplasty.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Vancomycin and Tobramycin at 1, 4, and 24 Hours.</measure>
    <time_frame>1 hour, 4 hours, and 24 hours</time_frame>
    <description>2. Determine the serum concentrations of these antibiotics postoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Antibotics in Cementless Knees</condition>
  <arm_group>
    <arm_group_label>Vancomycin Powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients getting vancomycin to see concentration after 24hrs in knee drain and serum levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobramycin Powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients getting Tobramycin to see conceration after 24hrs in knee drain and serum levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin Powder</intervention_name>
    <description>Everyone gets tobramycin powder.</description>
    <arm_group_label>Tobramycin Powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vancomyscin</intervention_name>
    <description>Everyone gets the vancomyscin powder.</description>
    <arm_group_label>Vancomycin Powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age over 18&#xD;
&#xD;
          2. Total knee arthroplasty for primary osteoarthritis. Primary diagnosis of knee&#xD;
             osteoarthritis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diminished mental capacity&#xD;
&#xD;
          2. Vancomycin allergy&#xD;
&#xD;
          3. Tobramycin allergy&#xD;
&#xD;
          4. Chronic kidney disease stage III and stage IV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <results_first_submitted>August 4, 2021</results_first_submitted>
  <results_first_submitted_qc>September 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2021</results_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT04297631/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT04297631/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vancomycin</title>
          <description>All patients getting vancomycin and tobramycin to see concentration after 24hrs in knee drain and serum levels.&#xD;
Vancomyscin: Everyone gets the vancomyscin powder.&#xD;
Tobramycin Powder: Everyone gets tobramycin powder.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vancomycin</title>
          <description>All patients getting vancomycin and tobramycin to see concentration after 24hrs in knee drain and serum levels.&#xD;
Vancomyscin: Everyone gets the vancomyscin powder.&#xD;
Tobramycin Powder: Everyone gets tobramycin powder.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vancomycin</title>
          <description>All patients getting vancomycin and tobramycin to see concentration after 24hrs in knee drain and serum levels.&#xD;
Vancomyscin: Everyone gets the vancomyscin powder. Tobramycin Powder: Everyone gets tobramycin powder.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Antibiotics in Cementless Knees Post op</title>
        <description>1. Determine the intra-articular concentration of vancomycin and tobramycin after administration of vancomycin and tobramycin powder in primary cementless total knee arthroplasty.</description>
        <time_frame>1 hour, 4 hours, and 24 hours</time_frame>
        <population>All primary cementless TKA two surgeons at a single institution over a 4-week period were assessed preoperatively for study inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Intraarticular Concentrations of Tobramycin and Vancomycin</title>
            <description>All patients getting vancomycin and tobramycin to see serum concentration after 24hrs in knee drain and serum levels.&#xD;
Vancomyscin: Everyone gets the vancomyscin powder.&#xD;
Tobramycin Powder: Everyone gets tobramycin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Antibiotics in Cementless Knees Post op</title>
          <description>1. Determine the intra-articular concentration of vancomycin and tobramycin after administration of vancomycin and tobramycin powder in primary cementless total knee arthroplasty.</description>
          <population>All primary cementless TKA two surgeons at a single institution over a 4-week period were assessed preoperatively for study inclusion.</population>
          <units>micrograms per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour Vancomycin Intraarticular concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1702.5" lower_limit="440" upper_limit="4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour Vancomycin Intraarticular concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="582.5" lower_limit="61" upper_limit="2400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour Vancomycin Intraarticular concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" lower_limit="12.4" upper_limit="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour tobramycin Intraarticular concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1943" lower_limit="345" upper_limit="7850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour tobramycin Intraarticular concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345" lower_limit="31.8" upper_limit="1150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour tobramycin Intraarticular concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="1.5" upper_limit="358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Vancomycin and Tobramycin at 1, 4, and 24 Hours.</title>
        <description>2. Determine the serum concentrations of these antibiotics postoperatively</description>
        <time_frame>1 hour, 4 hours, and 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vancomycin and Tobramycin Serum Concentration</title>
            <description>All patients getting vancomycin and tobramycin to see concentration after 24hrs in knee drain and serum levels.&#xD;
Vancomyscin: Everyone gets the vancomyscin powder.&#xD;
Tobramycin Powder: Everyone gets tobramycin powder.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Vancomycin and Tobramycin at 1, 4, and 24 Hours.</title>
          <description>2. Determine the serum concentrations of these antibiotics postoperatively</description>
          <units>micrograms per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour vancomycin serum concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour vancomycin serum concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="0" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour vancomycin serum concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="0" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour tobramycin serum concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="3.2" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 tobramycin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3.1" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour tobramycin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".8" lower_limit="0.5" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were captured while patient was in hospital which was about 24 hours.</time_frame>
      <desc>study involved collecting fluid and blood from patients at post-op timepoints.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intraarticular Concentrations of Tobramycin and Vancomycin</title>
          <description>All patients getting vancomycin and tobramycin to see serum concentration after 24hrs in knee drain and serum levels.&#xD;
Vancomyscin: Everyone gets the vancomyscin powder.&#xD;
Tobramycin Powder: Everyone gets tobramycin powder.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Venessa Riegler</name_or_title>
      <organization>Washington University</organization>
      <phone>3143621721</phone>
      <email>rieglerv@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

